Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acetylcysteine injection - Cumberland Pharmaceuticals

Drug Profile

Acetylcysteine injection - Cumberland Pharmaceuticals

Alternative Names: N-acetylcysteine (NAC) injection - Cumberland Pharmaceuticals; Acetadote; Intravenous NAC - Cumberland Pharmaceuticals

Latest Information Update: 31 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Cumberland Pharmaceuticals; GerminMED; Harbin Gloria Pharmaceuticals
  • Class Antibronchitics; Antidotes; Expectorants; Reducing agents; Small molecules; Sulfur amino acids
  • Mechanism of Action Antioxidants; Free radical inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Poisoning
  • New Molecular Entity No

Highest Development Phases

  • Marketed Poisoning
  • Phase II Kidney disorders
  • Discontinued Liver failure

Most Recent Events

  • 15 May 2019 Acetylcysteine injection licensed to Winhealth Pharma in China, Hong Kong and Macau
  • 04 Jan 2018 Phase II development is ongoing in Kidney disorders (Prevention) in USA
  • 04 Jan 2018 Cumberland Pharmaceuticals completes a phase II trial in Kidney disorders (Prevention) in USA (IV) (NCT00780962)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top